499 related articles for article (PubMed ID: 19651369)
1. Efficiency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets.
Getman D; Aiyer A; Dockter J; Giachetti C; Zhang F; Ginocchio CC
J Clin Virol; 2009 Jul; 45 Suppl 1():S49-54. PubMed ID: 19651369
[TBL] [Abstract][Full Text] [Related]
2. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
3. Analytical characterization of the APTIMA HPV Assay.
Dockter J; Schroder A; Eaton B; Wang A; Sikhamsay N; Morales L; Giachetti C
J Clin Virol; 2009 Jul; 45 Suppl 1():S39-47. PubMed ID: 19651368
[TBL] [Abstract][Full Text] [Related]
4. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
5. The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform.
Eder PS; Lou J; Huff J; Macioszek J
J Clin Virol; 2009 Jul; 45 Suppl 1():S85-92. PubMed ID: 19651374
[TBL] [Abstract][Full Text] [Related]
6. NucliSENS EasyQ HPV v1 test - Testing for oncogenic activity of human papillomaviruses.
Jeantet D; Schwarzmann F; Tromp J; Melchers WJ; van der Wurff AA; Oosterlaken T; Jacobs M; Troesch A
J Clin Virol; 2009 Jul; 45 Suppl 1():S29-37. PubMed ID: 19651366
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
9. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
[TBL] [Abstract][Full Text] [Related]
10. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
[TBL] [Abstract][Full Text] [Related]
11. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
13. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
14. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay.
Halfon P; Benmoura D; Agostini A; Khiri H; Martineau A; Penaranda G; Blanc B
J Clin Virol; 2010 Feb; 47(2):177-81. PubMed ID: 20022804
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay.
Rebolj M; Preisler S; Ejegod DM; Bonde J; Rygaard C; Lynge E
J Mol Diagn; 2013 Sep; 15(5):670-7. PubMed ID: 23827659
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of accuracy of three assays for human papillomavirus detection and typing: Hybrid Capture 2, HPV Consensus kit and Amplicor HPV].
Hantz S; Caly H; Decroisette E; Dutrop A; Bakeland D; Pascal B; Darreye G; Dussartre C; Renaudie J; Rogez S; Aubard Y; Denis F; Alain S
Pathol Biol (Paris); 2008 Feb; 56(1):29-35. PubMed ID: 18178026
[TBL] [Abstract][Full Text] [Related]
17. Validation of ThermoFisher's Papspin for human papillomavirus detection in cervicovaginal specimens using PCR with GP5+/GP6+ primers and the Hybrid Capture II assay.
Weynand B; Delvenne P; Polet R; Guiot Y; Arafa M; Somja J; Galant C
Clin Microbiol Infect; 2010 Jun; 16(6):671-5. PubMed ID: 19689463
[TBL] [Abstract][Full Text] [Related]
18. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
20. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses.
Molden T; Kraus I; Skomedal H; Nordstrøm T; Karlsen F
J Virol Methods; 2007 Jun; 142(1-2):204-12. PubMed ID: 17379322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
